Eli Lilly Stock Could Surge 45% in 2026 as Obesity Drug Sales Explode
Eli Lilly (NYSE: LLY) is entering 2026 with explosive revenue growth, strong momentum in its powerful obesity drug, and multiple Phase 3 catalysts. With guidance pointing toward $83 billion in revenue and analysts targeting major upside, this healthcare giant could still have significant room to run. Stock prices used were the market prices of Feb. … Read more
